DUBLIN--(BUSINESS WIRE)--The "Hypercholesterolemia Drugs Market: Global Industry Analysis, Trends, Market Size and Forecasts up to 2024" report has been added to ResearchAndMarkets.com's offering.
This report predicts the global hypercholesterolemia drugs market to grow with a CAGR of 4.7% over the forecast period of 2018-2024.
The report is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global hypercholesterolemia drugs market over the period of 2016 to 2024.
Growing responsiveness to heart diseases associated with aging population is the key factor driving the growth of the market. Additionally, availability of funding and activities to promote health awareness programs by healthcare centers, rise in incidence of cardiovascular diseases and increasing awareness among people for reducing the harmful cholesterol levels to control heart diseases such factors are likely to boost the growth in this market.
Statins is expected to be largest segment among the drug class in 2016. Statins helps to reduce blood cholesterol levels, bring down the danger of chest pain, heart attack, and stroke caused by a blocked blood vessel.
Key Topics Covered
2. Executive Summary
3. Global Hypercholesterolemia Drugs Market Overview
4. Global Hypercholesterolemia Drugs Market by Drug Class
5. Global Hypercholesterolemia Drugs Market by Type of Disease
6. Global Hypercholesterolemia Drugs Market by Mechanism of Action
6.1. Bile Acid Sequestrants
6.2. HMG-Coa Reductase Inhibitors
6.3. Fibric Acid Derivatives
6.4. Nicotinic Acid
7. Global Hypercholesterolemia Drugs Market by Region 2018-2024
8. Company Covered
8.1. Aegerion Pharmaceuticals
8.2. Amgen Inc.
8.3. Abbvie Inc.
8.4. Eli Lilly
8.5. Merck & Co. Inc.
8.6. Pfizer Inc.
8.7. Sanofi S.A.
8.8. Teva Pharmaceuticals
8.9. Cipla Limited
For more information about this report visit https://www.researchandmarkets.com/research/xj266l/global?w=4